Loading company…
Zafrens develops an experimental platform for studying cells and therapeutic modalities.
Founded in 2022 and based in San Diego, US, Zafrens develops an experimental platform that supports studies with single-cell CITE-seq precision. The platform is designed to produce insights across different therapeutic modalities with time and cost comparable to a conventional 96-well plate experiment. In February 2025, the company raised an undisclosed amount in Series A funding from imec.xpand, with participation from Prime Movers Lab, KOFA Healthcare Investments, and Global Brain. It planned to build capabilities and form pharmaceutical partnerships.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in